FDA Clears Big Health's SleepioRx for Insomnia Treatment

Big Health has achieved a key milestone with FDA 510(k) clearance for its digital therapeutic, SleepioRx, designed to treat insomnia by focusing on cognitive-behavioral strategies. SleepioRx offers a 90-day treatment program that personalizes care through symptom tracking and sleep monitoring, helping users address the underlying behavioral causes of insomnia. This approval positions SleepioRx as a guideline-recommended, non-medication alternative for insomnia, especially in light of new reimbursement codes that may encourage healthcare providers to prescribe digital therapeutics.

The FDA clearance underscores the growing role of digital therapeutics in healthcare, particularly for conditions like insomnia, where traditional treatments have often relied on medication. SleepioRx stands out for its evidence-based approach, leveraging cognitive-behavioral therapy (CBT) to teach patients how to manage behaviors contributing to sleep disorders. The platform offers customized goal setting, a detailed sleep diary, and real-time support, empowering users to track their progress and improve their sleep patterns effectively.

Big Health's advancements reflect the broader trend in digital health, where companies like Samsung and Apple are increasingly integrating sleep tracking features into consumer devices. While these tools offer valuable insights, SleepioRx's FDA clearance highlights its distinct clinical application in treating insomnia. With substantial funding and strategic acquisitions, Big Health is poised to lead in the digital therapeutics space, addressing critical needs in sleep health and beyond.

Click here to read the original news story.